Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling

(2014) K Kollmann et al.   LEUKEMIA

JAK Inhibitor in CALR-Mutant Myelofibrosis

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms

(2014) Paola Guglielmelli et al.   Expert Review of Hematology

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA

(2013) Daisuke Mashiko et al.   Scientific Reports

Orientation-specific signalling by thrombopoietin receptor dimers

(2011) Judith Staerk et al.   EMBO JOURNAL